Table 3.
Relationships between changes in indices for glucose metabolism associated with pemafibrate and changes in metabolic parameters in the 52-week study period.
| ΔHOMA-2R | ΔDI | |||
|---|---|---|---|---|
| Variables | ρ | p-Value | ρ | p-Value |
| ΔBMI (kg/m2) | 0.119 | 0.160 | −0.018 | 0.037 |
| ΔTriglyceride (mg/dL) | 0.265 | 0.002 | −0.258 | 0.002 |
| ΔHDL-C (ng/mL) | −0.190 | 0.002 | 0.130 | 0.124 |
| ΔAST (IU/L) | 0.017 | 0.838 | 0.032 | 0.709 |
| ΔALT (IU/L) | 0.148 | 0.079 | −0.142 | 0.093 |
| Δγ-GTP (IU/L) | 0.329 | <0.001 | −0.335 | <0.001 |
| ΔeGFR (mL/min/1.73 m2) | 0.017 | 0.838 | −0.161 | 0.058 |
p-values were obtained by Spearman’s rank correlation analysis. HOMA, homeostatic model assessment; DI, disposition index; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyl transpeptidase; eGFR, estimated glomerular filtration rate.